SABS
SAB Biotherapeutics, Inc.
$3.77
-0.13 (-3.33%)
At close · Jul 8
Market Cap
$302.80M
Shares
76,464,094
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.77
Open$3.87
Day$3.72–3.90
52W$1.85–6.60
Avg vol 30d924K
Short int2.9M · 3.8% float · 3.4d
Short vol50%
DataFeb 2021–Jul 2026
Filing10-Q · May 12
Equibles Rating
blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+5%
above
Price vs 50-day avg
+2%
above
RSI (14)
50
neutral
MACD trend
Positive
52-week position
40%
mid-range
Momentum
relative strength
1-month return
+11%
trailing
6-month return
−4%
trailing
YTD return
+1%
this year
Relative strength
−12%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $4 — 50d above 200d
Institutional flow
Accumulating
+65% holders QoQ · +36 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
3.76% of float · ▲ +8.8% MoM · 3.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
79 holders — near 2-yr high, broad support
Squeeze score
42
elevated · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
EPS growth
+79%
Y/Y
Free cash flow
$-45.7M
Balance sheet
$10.5M
net cash
Quant / Vol
risk profile
Volatility
78%
annualized · 1-yr
Max drawdown
−34%
past year
ATR
6.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 12, 2026
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+5%
Bullish
Price vs 50-day avg
+2%
Bullish
RSI (14)
50
Neutral
MACD trend
Positive
Bullish
52-week position
40%
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $4 › 200d $4 — 50d above 200d
Institutional flow
Accumulating
+65% holders QoQ · +36 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
3.76% of float · ▲ +8.8% MoM · 3.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
79 holders — near 2-yr high, broad support
Price context
position in its 52-week range
52-wk low $2
Now $4 · 40%
52-wk high $7
vs 200-day avg +5%
vs 50-day avg +2%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SABS
this stock
SAB Biotherapeutics, Inc.
|
$302.80M | +0.8% | -100.0% | — | 3.8% |
|
ONC
BeOne Medicines Ltd.
|
$436.30B | -0.6% | +22179.2% | 887.9 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$126.50B | +9.9% | +46.2% | 29.6 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.50B | -14.0% | +20.8% | 16.2 | 3.2% |
|
ARGX
Argenx SE
|
$57.20B | +8.8% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SABS | -3.3% | +10.9% | -4.3% | -3.3% | +0.8% |
| SPY | -0.2% | +0.8% | +7.4% | -0.2% | +9.3% |
| vs SPY | -3.2% | +10.0% | -11.8% | -3.2% | -8.5% |